These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34642875)

  • 1. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).
    Horn A; Krist L; Lieb W; Montellano FA; Kohls M; Haas K; Gelbrich G; Bolay-Gehrig SJ; Morbach C; Reese JP; Störk S; Fricke J; Zoller T; Schmidt S; Triller P; Kretzler L; Rönnefarth M; Von Kalle C; Willich SN; Kurth F; Steinbeis F; Witzenrath M; Bahmer T; Hermes A; Krawczak M; Reinke L; Maetzler C; Franzenburg J; Enderle J; Flinspach A; Vehreschild J; Schons M; Illig T; Anton G; Ungethüm K; Finkenberg BC; Gehrig MT; Savaskan N; Heuschmann PU; Keil T; Schreiber S
    Infection; 2021 Dec; 49(6):1277-1287. PubMed ID: 34642875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
    Bahmer T; Borzikowsky C; Lieb W; Horn A; Krist L; Fricke J; Scheibenbogen C; Rabe KF; Maetzler W; Maetzler C; Laudien M; Frank D; Ballhausen S; Hermes A; Miljukov O; Haeusler KG; Mokhtari NEE; Witzenrath M; Vehreschild JJ; Krefting D; Pape D; Montellano FA; Kohls M; Morbach C; Störk S; Reese JP; Keil T; Heuschmann P; Krawczak M; Schreiber S;
    EClinicalMedicine; 2022 Sep; 51():101549. PubMed ID: 35875815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
    Schons M; Pilgram L; Reese JP; Stecher M; Anton G; Appel KS; Bahmer T; Bartschke A; Bellinghausen C; Bernemann I; Brechtel M; Brinkmann F; Brünn C; Dhillon C; Fiessler C; Geisler R; Hamelmann E; Hansch S; Hanses F; Hanß S; Herold S; Heyder R; Hofmann AL; Hopff SM; Horn A; Jakob C; Jiru-Hillmann S; Keil T; Khodamoradi Y; Kohls M; Kraus M; Krefting D; Kunze S; Kurth F; Lieb W; Lippert LJ; Lorbeer R; Lorenz-Depiereux B; Maetzler C; Miljukov O; Nauck M; Pape D; Püntmann V; Reinke L; Römmele C; Rudolph S; Sass J; Schäfer C; Schaller J; Schattschneider M; Scheer C; Scherer M; Schmidt S; Schmidt J; Seibel K; Stahl D; Steinbeis F; Störk S; Tauchert M; Tebbe JJ; Thibeault C; Toepfner N; Ungethüm K; Vadasz I; Valentin H; Wiedmann S; Zoller T; Nagel E; Krawczak M; von Kalle C; Illig T; Schreiber S; Witzenrath M; Heuschmann P; Vehreschild JJ;
    Eur J Epidemiol; 2022 Aug; 37(8):849-870. PubMed ID: 35904671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).
    Steinbeis F; Thibeault C; Steinbrecher S; Ahlgrimm Y; Haack IA; August D; Balzuweit B; Bellinghausen C; Berger S; Chaplinskaya-Sobol I; Cornely O; Doeblin P; Endres M; Fink C; Finke C; Frank S; Hanß S; Hartung T; Hellmuth JC; Herold S; Heuschmann P; Heyckendorf J; Heyder R; Hippenstiel S; Hoffmann W; Kelle SU; Knape P; Koehler P; Kretzler L; Leistner DM; Lienau J; Lorbeer R; Lorenz-Depiereux B; Lüttke CD; Mai K; Merle U; Meyer-Arndt LA; Miljukov O; Muenchhoff M; Müller-Plathe M; Neuhann J; Neuhauser H; Nieters A; Otte C; Pape D; Pinto RM; Pley C; Pudszuhn A; Reuken P; Rieg S; Ritter P; Rohde G; Rönnefarth M; Ruzicka M; Schaller J; Schmidt A; Schmidt S; Schwachmeyer V; Schwanitz G; Seeger W; Stahl D; Stobäus N; Stubbe HC; Suttorp N; Temmesfeld B; Thun S; Triller P; Trinkmann F; Vadasz I; Valentin H; Vehreschild M; von Kalle C; von Lilienfeld-Toal M; Weber J; Welte T; Wildberg C; Wizimirski R; Zvork S; Sander LE; Vehreschild J; Zoller T; Kurth F; Witzenrath M
    Infection; 2024 Feb; 52(1):93-104. PubMed ID: 37434025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study.
    Hartung TJ; Bahmer T; Chaplinskaya-Sobol I; Deckert J; Endres M; Franzpötter K; Geritz J; Haeusler KG; Hein G; Heuschmann PU; Hopff SM; Horn A; Keil T; Krawczak M; Krist L; Lieb W; Maetzler C; Montellano FA; Morbach C; Neumann C; Nürnberger C; Russ AK; Schmidbauer L; Schmidt S; Schreiber S; Steigerwald F; Störk S; Zoller T; Maetzler W; Finke C;
    EClinicalMedicine; 2024 Mar; 69():102456. PubMed ID: 38333368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Integration of Inventory Data from Cohort and Registry Studies into an Existing Research Network: National Pandemic Cohort Network (NAPKON)].
    Hofmann AL; Vehreschild JJ; Witzenrath M; Hoffmann W; Illig T; Schreiber S; Anton G; Hellmuth JC; Muenchhoff M; Scherer C; Pley C; Thibeault C; Kurth F; Berger S; Hummel M; Hopff SM; Stecher M; Appel K; Stahl D; Kraus M; Lorenz-Depiereux B; Hanß S; von Kielmansegg S; Schlünder I; Niemeyer A; Heuschmann P; Krawczak M; Reese JP
    Gesundheitswesen; 2024 Oct; 86(10):647-654. PubMed ID: 39173676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
    Shi Y; Strobl R; Apfelbacher C; Bahmer T; Geisler R; Heuschmann P; Horn A; Hoven H; Keil T; Krawczak M; Krist L; Lemhöfer C; Lieb W; Lorenz-Depiereux B; Mikolajczyk R; Montellano FA; Reese JP; Schreiber S; Skoetz N; Störk S; Vehreschild JJ; Witzenrath M; Grill E;
    Infection; 2023 Dec; 51(6):1679-1694. PubMed ID: 37231313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Return-to-work, disabilities and occupational health in the age of COVID-19.
    Godeau D; Petit A; Richard I; Roquelaure Y; Descatha A
    Scand J Work Environ Health; 2021 Jul; 47(5):408-409. PubMed ID: 34003294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression and fatigue six months post-COVID-19 disease are associated with overlapping symptom constellations: A prospective, multi-center, population-based cohort study.
    Weiß M; Gutzeit J; Appel KS; Bahmer T; Beutel M; Deckert J; Fricke J; Hanß S; Hettich-Damm N; Heuschmann PU; Horn A; Jauch-Chara K; Kohls M; Krist L; Lorenz-Depiereux B; Otte C; Pape D; Reese JP; Schreiber S; Störk S; Vehreschild JJ; Hein G;
    J Affect Disord; 2024 May; 352():296-305. PubMed ID: 38360365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study.
    Balck A; Föh B; Borsche M; Rahmöller J; Vollstedt EJ; Waldeck F; Käding N; Twesten C; Mischnik A; Gillessen-Kaesbach G; Ehlers M; Sina C; Taube S; Busch H; Rupp J; Katalinic A; Klein C
    BMC Public Health; 2022 Jul; 22(1):1305. PubMed ID: 35799167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19): structured summary of a study protocol for a randomised controlled trial.
    Elder GJ; Alfonso-Miller P; Atkinson WCM; Santhi N; Ellis JG
    Trials; 2020 Aug; 21(1):704. PubMed ID: 32771068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up.
    Heidemann C; Sarganas G; Du Y; Gaertner B; Poethko-Müller C; Cohrdes C; Schmidt S; Schlaud M; Scheidt-Nave C
    BMC Public Health; 2023 Aug; 23(1):1587. PubMed ID: 37605232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.